Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Matthew A. Hummel"'
Autor:
Mark A. Socinski, Cornelius F. Waller, Tazeen Idris, Igor Bondarenko, Alexander Luft, Katrin Beckmann, Ashwini Vishweswaramurthy, Subramanian Loganathan, Charles Donnelly, Matthew A. Hummel, Roxann Shapiro, Melody Woods, Anita Rao, Vivek G Nayak, Gopinath Ranganna, Abhijit Barve
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. Patients and methods: Patien
Externí odkaz:
https://doaj.org/article/c16131d828264fbc8bb2cf1ee253522f
Autor:
Tjerk Bosje, Mark A. Socinski, Abhijit Barve, Andrew D. Shaw, Mudgal Kothekar, Mark Liu, Cornelius F. Waller, Matthew A. Hummel
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor-specific angiogenesis in some cancers. MYL-1402O is a proposed bevacizumab biosimilar. Methods The primary objective of this single-ce
Autor:
Mark A. Socinski, Matthew A. Hummel, Cornelius F. Waller, Russell J. Rackley, Tazeen Idris, Joel Owen, Sundara Moorthi Nainar Murugesan, Gopinath Ranganna, Mark Liu, Stefan Roepcke, Ashwini Vishweswaramurthy, Hannah Huang, Abhijit Barve, Subramanian Loganathan
Publikováno v:
Journal of Clinical Oncology. 39:e21087-e21087
e21087 Background: MYL-1402O (MYL) is a proposed biosimilar to bevacizumab reference product. A multicenter, double blind randomized, phase 3 study compared the efficacy, safety, PK, and immunogenicity of MYL and Avastin in patients with Stage IV met
Autor:
Cornelius F. Waller, Mark A. Socinski, Igor Bondarenko, Vivek G Nayak, Melody Woods, Matthew A. Hummel, Ashwini Vishweswaramurthy, Gopinath Ranganna, Roxann Shapiro, Katrin Beckmann, Subramanian Loganathan, Tazeen Idris, Anita Rao, Alexander Luft, Abhijit Barve, Charles Donnelly
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. Patients and methods: Patien
Publikováno v:
The Journal of Arthroplasty. 24:73-76
The purpose of this study was to determine if the use of both a larger femoral head size and a posterior capsular repair would lead to a decreased incidence of dislocation following revision total hip arthroplasty (THA). Two hundred forty-two consecu
Publikováno v:
The Journal of Arthroplasty. 23:822-825
This study retrospectively contrasts 2 cohorts of consecutive patients ""(N = 202) after primary total knee arthroplasty with respect to the types and numbers of patella and extensor mechanism complications. Our results demonstrated an overall decrea
Publikováno v:
Archives of Biochemistry and Biophysics. 475:175-183
CYP2C9 polymorphisms result in reduced enzyme catalytic activity and greater activation by effector molecules as compared to wild-type protein, with the mechanism(s) for these changes in activity not fully elucidated. Through T(1) NMR and spectral bi
Publikováno v:
Biochemistry. 43:7207-7214
Cytochrome P450 2C9 (CYP2C9)-mediated flurbiprofen 4'-hydroxylation is activated by the presence of dapsone resulting in reduction of the K(m) for flurbiprofen hydroxylation and an increase in V(m). Previous spectral binding studies have demonstrated
Autor:
Timothy S. Tracy, Matthew A. Hummel
Publikováno v:
Drug Metabolism Reviews. 36:231-242
Modeling of in vitro enzyme kinetic data derived from drug metabolism experiments can greatly facilitate the drug development process because estimation of kinetic parameters can facilitate decision making regarding whether to continue development of